Related references
Note: Only part of the references are listed.Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement
ANNALS OF INTERNAL MEDICINE (2013)
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
Chunyu Zhang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the US Preventive Services Task Force
Tracy Wolff et al.
ANNALS OF INTERNAL MEDICINE (2009)
Aspirin for the Primary Prevention of Cardiovascular Events A systematic review and meta-analysis comparing patients with and without diabetes
Andrew D. Calvin et al.
DIABETES CARE (2009)
Aspirin Resistance Transient Laboratory Finding or Important Clinical Entity?
Eli I. Lev
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays Implications for Aspirin Resistance
Francesca Santilli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
LANCET (2009)
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Giorgia De Berardis et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents
Arun Natarajan et al.
DIABETES & VASCULAR DISEASE RESEARCH (2008)
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes A Randomized Controlled Trial
Hisao Ogawa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
LANCET (2008)
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
Jill Belch et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Mechanisms of disease:: Platelet activation and atherothrombosis
Giovanni Davi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT- D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
Giorgia De Berardis et al.
TRIALS (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
DIABETES CARE (2007)
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications
Sonia Hernandez-Diaz et al.
BMC MEDICINE (2006)
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis
M Pignone et al.
ANNALS OF INTERNAL MEDICINE (2006)
Aspirin for the primary prevention of cardiovascular events in women and men - A sex-specific meta-analysis of randomized controlled trials
JS Berger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicyclic acid (aspirin) - its relation to metabolic control
C Watala et al.
THROMBOSIS RESEARCH (2004)
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial
M Sacco et al.
DIABETES CARE (2003)
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use
KC Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
JW Eikelboom et al.
CIRCULATION (2002)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
